Kisch Annika M, Winterling Jeanette, Hägglund Hans, Larfors Gunnar, Lenhoff Stig, Pahnke Simon
Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Institute of Health Sciences, Lund University, Lund, Sweden.
J Clin Apher. 2025 Aug;40(4):e70050. doi: 10.1002/jca.70050.
The aim was to describe hematopoietic stem cell (HSC) donors' experiences focusing on information and side effects during the first year after donation. Our prospective Swedish cohort study with adult HSC donors was performed from 2019 to 2022, with questionnaires at four time points from before until 12 months after donation. 173 unrelated and 68 related donors participated, and the majority donated peripheral blood stem cells. All but one rated their donation experience as good or very good. At least one side effect was reported by 83% of participants. Six donors (2.5%) experienced either numerous side effects, at least one severe side effect, or prolonged side effects. Satisfaction with information was lower among donors having severe side effects and bone marrow donors. Overall satisfaction with the donation was lower among donors having severe side effects and unrelated donors. Donors were generally satisfied with the pre-donation information. Most experienced side effects that resolved within 2 weeks, which strengthens the case for unchanged donor follow-up 1 month after donation, with individualized follow-up for donors with persistent symptoms. Enhanced information regarding the risk of more severe or prolonged side effects appears warranted, and its effect on donor satisfaction should be evaluated.
目的是描述造血干细胞（HSC）捐献者在捐献后第一年的经历，重点关注信息和副作用。我们对成年HSC捐献者进行的前瞻性瑞典队列研究于2019年至2022年开展，在捐献前至捐献后12个月的四个时间点进行问卷调查。173名非亲属捐献者和68名亲属捐献者参与其中，大多数捐献外周血干细胞。除一人外，所有捐献者都将他们的捐献经历评为良好或非常好。83%的参与者报告了至少一种副作用。六名捐献者（2.5%）经历了多种副作用、至少一种严重副作用或长期副作用。有严重副作用的捐献者和骨髓捐献者对信息披露的满意度较低。有严重副作用的捐献者和非亲属捐献者对捐献的总体满意度较低。捐献者总体上对捐献前的信息披露感到满意。大多数副作用在2周内得到缓解，这支持了在捐献后1个月维持不变的捐献者随访方式，对有持续症状的捐献者进行个性化随访。似乎有必要提供更多关于更严重或长期副作用风险的信息，并应评估其对捐献者满意度的影响。
